{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:48:43Z","timestamp":1790812123638,"version":"4.1.0"},"reference-count":114,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R35-GM124836"],"award-info":[{"award-number":["R35-GM124836"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007261","name":"New York Academy of Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007261","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01-AG061186-04"],"award-info":[{"award-number":["R01-AG061186-04"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015993","name":"Kowa Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015993","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.pharmthera.2023.108544","type":"journal-article","created":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T01:27:05Z","timestamp":1697333225000},"page":"108544","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Severe hypertriglyceridemia: Existing and emerging therapies"],"prefix":"10.1016","volume":"251","author":[{"given":"Waqas A.","family":"Malick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Do","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Rosenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.pharmthera.2023.108544_bb0005","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1152\/physrev.00019.2011","article-title":"Role of the gut in lipid homeostasis","volume":"92","author":"Abumrad","year":"2012","journal-title":"Physiological Reviews"},{"issue":"9","key":"10.1016\/j.pharmthera.2023.108544_bb0010","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1194\/jlr.RA120000888","article-title":"Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance","volume":"61","author":"Adam","year":"2020","journal-title":"Journal of Lipid Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108544_bb0015","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.atherosclerosis.2012.02.001","article-title":"Postprandial accumulation of chylomicrons and chylomicron remnants is determined by the clearance capacity","volume":"222","author":"Adiels","year":"2012","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.pharmthera.2023.108544_bb0020","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1161\/CIRCULATIONAHA.118.039107","article-title":"Inhibition of angiopoietin-like protein 3 with a monoclonal antibody reduces triglycerides in hypertriglyceridemia","volume":"140","author":"Ahmad","year":"2019","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.pharmthera.2023.108544_bb0025","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jacc.2021.04.091","article-title":"Inhibition of angiopoietin-like protein 3 with Evinacumab in subjects with high and severe hypertriglyceridemia","volume":"78","author":"Ahmad","year":"2021","journal-title":"Journal of the American College of Cardiology"},{"issue":"33","key":"10.1016\/j.pharmthera.2023.108544_bb0030","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1093\/eurheartj\/ehz209","article-title":"N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels","volume":"40","author":"Alexander","year":"2019","journal-title":"European Heart Journal"},{"issue":"2","key":"10.1016\/j.pharmthera.2023.108544_bb0035","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1001\/jama.1996.03530260042029","article-title":"Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia","volume":"275","author":"Bakker-Arkema","year":"1996","journal-title":"Jama"},{"issue":"5","key":"10.1016\/j.pharmthera.2023.108544_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2022.100198","article-title":"An anti-ANGPTL3\/8 antibody decreases circulating triglycerides by binding to a LPL-inhibitory leucine zipper-like motif","volume":"63","author":"Balasubramaniam","year":"2022","journal-title":"Journal of Lipid Research"},{"key":"10.1016\/j.pharmthera.2023.108544_bb0045","series-title":"ARO-APOC3, an investigational RNAi therapeutic, decreases serum apolipoprotein C3, triglyceride, and non-HDL-C concentrations while increasing HDL-C in patients with severe hypertriglyceridemia","author":"Ballantyne","year":"2022"},{"key":"10.1016\/j.pharmthera.2023.108544_bb0050","series-title":"Prevalence of NAFLD in subjects with severe hypertriglyceridemia: Initial baseline data from an ongoing phase 2 study","author":"Bays","year":"2021"},{"issue":"5","key":"10.1016\/j.pharmthera.2023.108544_bb0055","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.amjcard.2011.04.015","article-title":"Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the multi-center, plAcebo-controlled, randomized, double-blINd, 12-week study with an open-label extension [MARINE] trial)","volume":"108","author":"Bays","year":"2011","journal-title":"The American Journal of Cardiology"},{"issue":"7","key":"10.1016\/j.pharmthera.2023.108544_bb0060","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1038\/s41591-023-02427-z","article-title":"The FGF21 analog pegozafermin in severe hypertriglyceridemia: A randomized phase 2 trial","volume":"29","author":"Bhatt","year":"2023","journal-title":"Nature Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108544_bb0065","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with Icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108544_bib572","first-page":"21","volume":"102","year":"2000","journal-title":"Bezafibrate Infarction Prevention (BIP) study. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation"},{"issue":"14","key":"10.1016\/j.pharmthera.2023.108544_bb0070","doi-asserted-by":"crossref","first-page":"9858","DOI":"10.1016\/S0021-9258(19)50173-9","article-title":"The assembly and secretion of ApoB 100-containing lipoproteins in Hep G2 cells. ApoB 100 is cotranslationally integrated into lipoproteins","volume":"267","author":"Bor\u00e9n","year":"1992","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2023.108544_bb0075","doi-asserted-by":"crossref","first-page":"474","DOI":"10.3389\/fendo.2020.00474","article-title":"The roles of ApoC-III on the metabolism of triglyceride-rich lipoproteins in humans","volume":"11","author":"Bor\u00e9n","year":"2020","journal-title":"Frontiers in Endocrinology"},{"issue":"6","key":"10.1016\/j.pharmthera.2023.108544_bb0080","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.jacl.2022.08.009","article-title":"Guidance for the diagnosis and treatment of hypolipidemia disorders","volume":"16","author":"Bredefeld","year":"2022","journal-title":"Journal of Clinical Lipidology"},{"issue":"8","key":"10.1016\/j.pharmthera.2023.108544_bb0085","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1194\/jlr.RA120000781","article-title":"Angiopoietin-like protein 8 differentially regulates ANGPTL3 and ANGPTL4 during postprandial partitioning of fatty acids","volume":"61","author":"Chen","year":"2020","journal-title":"Journal of Lipid Research"},{"issue":"Suppl_1","key":"10.1016\/j.pharmthera.2023.108544_bb0095","doi-asserted-by":"crossref","first-page":"A10357","DOI":"10.1161\/circ.144.suppl_1.10357","article-title":"Abstract 10357: ARO-APOC3, an investigational RNAi therapeutic, shows similar efficacy and safety in genetically confirmed FCS and non-FCS participants with severe hypertriglyceridemia","volume":"144","author":"Clifton","year":"2021","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.pharmthera.2023.108544_bb0100","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1016\/S0022-2275(20)35345-1","article-title":"Contribution of apoB-48 and apoB-100 triglyceride-rich lipoproteins (TRL) to postprandial increases in the plasma concentration of TRL triglycerides and retinyl esters","volume":"34","author":"Cohn","year":"1993","journal-title":"Journal of Lipid Research"},{"issue":"7","key":"10.1016\/j.pharmthera.2023.108544_bb0105","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0022-2275(20)38485-6","article-title":"Plasma apolipoprotein changes in the triglyceride-rich lipoprotein fraction of human subjects fed a fat-rich meal","volume":"29","author":"Cohn","year":"1988","journal-title":"Journal of Lipid Research"},{"key":"10.1016\/j.pharmthera.2023.108544_bb0573","doi-asserted-by":"crossref","unstructured":"HPS2-THRIVE Collaborative Group; Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, Tomson J, Wallendszus K, Craig M, Jiang L, Collins R, Armitage J. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014 Jul 17;371(3):203-12.","DOI":"10.1056\/NEJMoa1300955"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108544_bb0110","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1307095","article-title":"Loss-of-function mutations in APOC3, triglycerides, and coronary disease","volume":"371","author":"Crosby","year":"2014","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2023.108544_bb0115","series-title":"Randomized trial for evaluation in secondary prevention efficacy of combination therapy\u2013statin and eicosapentaenoic acid - RESPECT-EPA","author":"Daida","year":"2022"},{"issue":"21","key":"10.1016\/j.pharmthera.2023.108544_bb0120","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with Pemafibrate to reduce cardiovascular risk","volume":"387","author":"Das Pradhan","year":"2022","journal-title":"The New England Journal of Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108544_bb0125","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/MOL.0000000000000252","article-title":"Effects of bariatric surgery on hepatic and intestinal lipoprotein particle metabolism","volume":"27","author":"Dash","year":"2016","journal-title":"Current Opinion in Lipidology"},{"issue":"7","key":"10.1016\/j.pharmthera.2023.108544_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2022.100237","article-title":"ANGPTL4 silencing via antisense oligonucleotides reduces plasma triglycerides and glucose in mice without causing lymphadenopathy","volume":"63","author":"Deng","year":"2022","journal-title":"Journal of Lipid Research"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108544_bb0135","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1612790","article-title":"Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease","volume":"377","author":"Dewey","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"12","key":"10.1016\/j.pharmthera.2023.108544_bb0140","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1056\/NEJMoa1510926","article-title":"Inactivating variants in ANGPTL4 and risk of coronary artery disease","volume":"374","author":"Dewey","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2023.108544_bb0145","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease","volume":"115","author":"Donnelly","year":"2005","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2023.108544_bb0150","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3389\/fendo.2020.00455","article-title":"Genetics of Hypertriglyceridemia","volume":"11","author":"Dron","year":"2020","journal-title":"Frontiers in Endocrinology"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108544_bb0155","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/clinchem\/hvaa296","article-title":"Triglyceride-rich lipoprotein remnants and cardiovascular disease","volume":"67","author":"Duran","year":"2020","journal-title":"Clinical Chemistry"},{"issue":"11","key":"10.1016\/j.pharmthera.2023.108544_bb0160","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1172\/JCI119456","article-title":"Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E","volume":"99","author":"Ebara","year":"1997","journal-title":"The Journal of Clinical Investigation"},{"issue":"2","key":"10.1016\/j.pharmthera.2023.108544_bb0165","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2337\/diabetes.52.2.453","article-title":"Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance","volume":"52","author":"Garvey","year":"2003","journal-title":"Diabetes"},{"issue":"23","key":"10.1016\/j.pharmthera.2023.108544_bb0170","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1056\/NEJMoa1400284","article-title":"Targeting APOC3 in the familial chylomicronemia syndrome","volume":"371","author":"Gaudet","year":"2014","journal-title":"New England Journal of Medicine"},{"issue":"10193","key":"10.1016\/j.pharmthera.2023.108544_bb0175","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"The Lancet"},{"issue":"5","key":"10.1016\/j.pharmthera.2023.108544_bb0180","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1172\/JCI112713","article-title":"Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo","volume":"78","author":"Ginsberg","year":"1986","journal-title":"The Journal of Clinical Investigation"},{"issue":"47","key":"10.1016\/j.pharmthera.2023.108544_bb0185","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: Metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies\u2014A consensus statement from the European Atherosclerosis Society","volume":"42","author":"Ginsberg","year":"2021","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2023.108544_bb0190","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.593931","article-title":"A comprehensive update on the chylomicronemia syndrome","volume":"11","author":"Goldberg","year":"2020","journal-title":"Frontiers in Endocrinology"},{"issue":"5","key":"10.1016\/j.pharmthera.2023.108544_bb0195","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S2213-8587(21)00046-2","article-title":"Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): A multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"9","author":"Gouni-Berthold","year":"2021","journal-title":"The Lancet Diabetes & Endocrinology"},{"issue":"25","key":"10.1016\/j.pharmthera.2023.108544_bb0200","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the Management of Blood Cholesterol: A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"issue":"14","key":"10.1016\/j.pharmthera.2023.108544_bb0205","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1001\/archinte.162.14.1568","article-title":"Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: Results of the assessment of diabetes control and evaluation of the efficacy of Niaspan trial","volume":"162","author":"Grundy","year":"2002","journal-title":"Archives of Internal Medicine"},{"issue":"6","key":"10.1016\/j.pharmthera.2023.108544_bb0210","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1194\/jlr.M075689","article-title":"ANGPTL8 requires ANGPTL3 to inhibit lipoprotein lipase and plasma triglyceride clearance[S]","volume":"58","author":"Haller","year":"2017","journal-title":"Journal of Lipid Research"},{"issue":"5\u20136","key":"10.1016\/j.pharmthera.2023.108544_bb0215","first-page":"385","article-title":"Safety and efficacy of Omacor in severe hypertriglyceridemia","volume":"4","author":"Harris","year":"1997","journal-title":"Journal of Cardiovascular Risk"},{"issue":"8","key":"10.1016\/j.pharmthera.2023.108544_bb0220","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S2213-8587(13)70191-8","article-title":"The polygenic nature of hypertriglyceridaemia: Implications for definition, diagnosis, and management","volume":"2","author":"Hegele","year":"2014","journal-title":"The Lancet Diabetes and Endocrinology"},{"issue":"13","key":"10.1016\/j.pharmthera.2023.108544_bb0225","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly Exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1016\/j.pharmthera.2023.108544_bb0230","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/00019501-200403000-00008","article-title":"Rosuvastatin improves the atherogenic and atheroprotective lipid profiles in patients with hypertriglyceridemia","volume":"15","author":"Hunninghake","year":"2004","journal-title":"Coronary Artery Disease"},{"key":"10.1016\/j.pharmthera.2023.108544_bb0574","doi-asserted-by":"crossref","unstructured":"AIM-HIGH Investigators; Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011 Dec 15;365(24):2255-67.","DOI":"10.1056\/NEJMoa1107579"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108544_bb0235","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1016\/j.pharmthera.2023.108544_bb0240","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1194\/jlr.R119000547","article-title":"Alcohol effects on hepatic lipid metabolism","volume":"61","author":"Jeon","year":"2020","journal-title":"Journal of Lipid Research"},{"issue":"5","key":"10.1016\/j.pharmthera.2023.108544_bb0245","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.bbalip.2011.10.007","article-title":"Allelic and phenotypic spectrum of plasma triglycerides","volume":"1821","author":"Johansen","year":"2012","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids"},{"issue":"2","key":"10.1016\/j.pharmthera.2023.108544_bb0250","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1194\/jlr.R009720","article-title":"Genetic determinants of plasma triglycerides","volume":"52","author":"Johansen","year":"2011","journal-title":"Journal of Lipid Research"},{"issue":"8","key":"10.1016\/j.pharmthera.2023.108544_bb0255","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1161\/ATVBAHA.111.226365","article-title":"An increased burden of common and rare lipid-associated risk alleles contributes to the phenotypic spectrum of hypertriglyceridemia","volume":"31","author":"Johansen","year":"2011","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108544_bb0260","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1308027","article-title":"Loss-of-function mutations in APOC3 and risk of ischemic vascular disease","volume":"371","author":"J\u00f8rgensen","year":"2014","journal-title":"The New England Journal of Medicine"},{"issue":"2","key":"10.1016\/j.pharmthera.2023.108544_bb0265","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1161\/01.ATV.15.2.199","article-title":"Quantification of postprandial triglyceride-rich lipoproteins in healthy men by retinyl ester labeling and simultaneous measurement of apolipoproteins B-48 and B-100","volume":"15","author":"Karpe","year":"1995","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108544_bb0270","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jacl.2013.10.003","article-title":"Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr lowering very high triglyceridEs (EVOLVE) trial","volume":"8","author":"Kastelein","year":"2014","journal-title":"Journal of Clinical Lipidology"},{"key":"10.1016\/j.pharmthera.2023.108544_bib571","doi-asserted-by":"crossref","unstructured":"Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kes\u00e4niemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005 Nov 26;366(9500):1849-61.","DOI":"10.1016\/S0140-6736(05)67667-2"},{"key":"10.1016\/j.pharmthera.2023.108544_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2021.100150","article-title":"Role and mechanism of the action of angiopoietin-like protein ANGPTL4 in plasma lipid metabolism","volume":"62","author":"Kersten","year":"2021","journal-title":"Journal of Lipid Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108544_bb0280","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.atherosclerosissup.2010.03.003","article-title":"The mechanism of the formation and secretion of chylomicrons","volume":"11","author":"Kindel","year":"2010","journal-title":"Atherosclerosis. Supplements"},{"issue":"5","key":"10.1016\/j.pharmthera.2023.108544_bb0285","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.bbalip.2012.01.006","article-title":"Postprandial metabolism of meal triglyceride in humans","volume":"1821","author":"Lambert","year":"2012","journal-title":"Biochimica et Biophysica Acta"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108544_bb0290","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s10545-013-9665-4","article-title":"Abetalipoproteinemia and homozygous hypobetalipoproteinemia: A framework for diagnosis and management","volume":"37","author":"Lee","year":"2014","journal-title":"Journal of Inherited Metabolic Disease"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108544_bb0295","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1210\/er.2014-1062","article-title":"Hypertriglyceridemia in the genomic era: A new paradigm","volume":"36","author":"Lewis","year":"2015","journal-title":"Endocrine Reviews"},{"key":"10.1016\/j.pharmthera.2023.108544_bb0300","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, controlled trial of the FGF21 analogue Pegozafermin in NASH","author":"Loomba","year":"2023","journal-title":"The New England Journal of Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108544_bb0305","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk: The task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2019","journal-title":"European Heart Journal"},{"issue":"16","key":"10.1016\/j.pharmthera.2023.108544_bb0310","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.jacc.2023.02.034","article-title":"Clinical trial Design for Triglyceride-Rich Lipoprotein-Lowering Therapies","volume":"81","author":"Malick","year":"2023","journal-title":"Journal of the American College of Cardiology"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108544_bb0315","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1811403","article-title":"Marine n\u22123 fatty acids and prevention of cardiovascular disease and cancer","volume":"380","author":"Manson","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108544_bb0320","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0021-9150(90)90054-M","article-title":"Effect of gemfibrozil on the concentration and composition of serum lipoproteins A controlled study with special reference to initial triglyceride levels","volume":"81","author":"M\u00e4ntt\u00e4ri","year":"1990","journal-title":"Atherosclerosis"},{"issue":"19","key":"10.1016\/j.pharmthera.2023.108544_bb0325","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1016\/j.pharmthera.2023.108544_bb0330","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"23","key":"10.1016\/j.pharmthera.2023.108544_bb0335","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1002926","article-title":"Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia","volume":"363","author":"Musunuru","year":"2010","journal-title":"The New England Journal of Medicine"},{"issue":"12","key":"10.1016\/j.pharmthera.2023.108544_bb0340","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1194\/jlr.M500335-JLR200","article-title":"Treatment with high-dose simvastatin reduces secretion of apolipoprotein B-lipoproteins in patients with diabetic dyslipidemia","volume":"46","author":"Myerson","year":"2005","journal-title":"Journal of Lipid Research"},{"issue":"6","key":"10.1016\/j.pharmthera.2023.108544_bb0345","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1161\/ATVBAHA.121.316311","article-title":"GLP-1 (glucagon-like Peptide-1) is physiologically relevant for chylomicron secretion beyond its known pharmacological role","volume":"41","author":"Nahmias","year":"2021","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"issue":"22","key":"10.1016\/j.pharmthera.2023.108544_bb0360","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1001\/jama.2020.22258","article-title":"Effect of high-dose Omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: The STRENGTH randomized clinical trial","volume":"324","author":"Nicholls","year":"2020","journal-title":"Jama"},{"issue":"12","key":"10.1016\/j.pharmthera.2023.108544_bb0365","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.jacc.2020.11.079","article-title":"New and emerging therapies for reduction of LDL-cholesterol and apolipoprotein B","volume":"77","author":"Nurmohamed","year":"2021","journal-title":"Journal of the American College of Cardiology"},{"issue":"10","key":"10.1016\/j.pharmthera.2023.108544_bb0370","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1194\/jlr.M094128","article-title":"Characterization of ANGPTL4 function in macrophages and adipocytes using Angptl4-knockout and Angptl4-hypomorphic mice[S]","volume":"60","author":"Oteng","year":"2019","journal-title":"Journal of Lipid Research"},{"issue":"8","key":"10.1016\/j.pharmthera.2023.108544_bb0375","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.cjca.2021.03.016","article-title":"2021 Canadian cardiovascular society guidelines for the Management of Dyslipidemia for the prevention of cardiovascular disease in adults","volume":"37","author":"Pearson","year":"2021","journal-title":"Canadian Journal of Cardiology"},{"issue":"12","key":"10.1016\/j.pharmthera.2023.108544_bb0380","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1001\/jamainternmed.2016.6875","article-title":"Nonfasting mild-to-moderate hypertriglyceridemia and risk of acute pancreatitis","volume":"176","author":"Pedersen","year":"2016","journal-title":"JAMA Internal Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108544_bb0385","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of Liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"5908","key":"10.1016\/j.pharmthera.2023.108544_bb0390","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1126\/science.1161524","article-title":"A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection","volume":"322","author":"Pollin","year":"2008","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.pharmthera.2023.108544_bb0395","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0021-9150(98)00301-3","article-title":"Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins","volume":"143","author":"Pownall","year":"1999","journal-title":"Atherosclerosis"},{"issue":"4","key":"10.1016\/j.pharmthera.2023.108544_bb0400","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/ng1984","article-title":"Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL","volume":"39","author":"Romeo","year":"2007","journal-title":"Nature Genetics"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108544_bb0405","first-page":"70","article-title":"Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans","volume":"119","author":"Romeo","year":"2009","journal-title":"The Journal of Clinical Investigation"},{"issue":"8","key":"10.1016\/j.pharmthera.2023.108544_bb0410","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1161\/ATVBAHA.121.316278","article-title":"Niacin increases Atherogenic proteins in high-density lipoprotein of statin-treated subjects","volume":"41","author":"Ronsein","year":"2021","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108544_bb0415","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/s41591-023-02222-w","article-title":"Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: A phase 2 randomized trial","volume":"29","author":"Rosenson","year":"2023","journal-title":"Nature Medicine"},{"issue":"18","key":"10.1016\/j.pharmthera.2023.108544_bb0420","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/j.jacc.2021.08.051","article-title":"New therapies for lowering triglyceride-rich lipoproteins: JACC focus seminar 3\/4","volume":"78","author":"Rosenson","year":"2021","journal-title":"Journal of the American College of Cardiology"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108544_bb0425","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/FJC.0b013e3181b0cf71","article-title":"Prescription omega-3 fatty acid as an adjunct to fenofibrate therapy in hypertriglyceridemic subjects","volume":"54","author":"Roth","year":"2009","journal-title":"Journal of Cardiovascular Pharmacology"},{"issue":"7","key":"10.1016\/j.pharmthera.2023.108544_bb0430","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1161\/01.ATV.17.7.1400","article-title":"Therapeutic response to medium-chain triglycerides and \u03c9-3 fatty acids in a patient with the familial Chylomicronemia syndrome","volume":"17","author":"Rouis","year":"1997","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108544_bb0435","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1001\/jamainternmed.2013.13309","article-title":"Severe hypertriglyceridemia with pancreatitis: Thirteen years\u2019 treatment with lomitapide","volume":"174","author":"Sacks","year":"2014","journal-title":"JAMA Internal Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108544_bb0440","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12944-021-01488-8","article-title":"The association of triglyceride levels with the incidence of initial and recurrent acute pancreatitis","volume":"20","author":"Sanchez","year":"2021","journal-title":"Lipids in Health and Disease"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108544_bb0445","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.cmet.2016.01.006","article-title":"FGF21 lowers plasma triglycerides by accelerating lipoprotein catabolism in white and brown adipose tissues","volume":"23","author":"Schlein","year":"2016","journal-title":"Cell Metabolism"},{"issue":"5","key":"10.1016\/j.pharmthera.2023.108544_bb0450","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1073\/pnas.90.5.2069","article-title":"Relationships between the responses of triglyceride-rich lipoproteins in blood plasma containing apolipoproteins B-48 and B-100 to a fat-containing meal in normolipidemic humans","volume":"90","author":"Schneeman","year":"1993","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108544_bb0455","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s10557-021-07168-0","article-title":"Genetics of triglyceride-rich lipoproteins guide identification of pharmacotherapy for cardiovascular risk reduction","volume":"35","author":"Shaik","year":"2021","journal-title":"Cardiovascular Drugs and Therapy"},{"key":"10.1016\/j.pharmthera.2023.108544_bb0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.plefa.2022.102450","article-title":"A biological rationale for the disparate effects of omega-3 fatty acids on cardiovascular disease outcomes","volume":"182","author":"Sherratt","year":"2022","journal-title":"Prostaglandins, Leukotrienes, and Essential Fatty Acids"},{"issue":"37","key":"10.1016\/j.pharmthera.2023.108544_bb0465","doi-asserted-by":"crossref","first-page":"33742","DOI":"10.1074\/jbc.M203215200","article-title":"ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase*","volume":"277","author":"Shimizugawa","year":"2002","journal-title":"Journal of Biological Chemistry"},{"issue":"17","key":"10.1016\/j.pharmthera.2023.108544_bb0470","doi-asserted-by":"crossref","DOI":"10.1172\/JCI140989","article-title":"Hepatocyte-specific suppression of ANGPTL4 improves obesity-associated diabetes and mitigates atherosclerosis in mice","volume":"131","author":"Singh","year":"2021","journal-title":"Journal of Clinical Investigation"},{"issue":"12","key":"10.1016\/j.pharmthera.2023.108544_bb0475","doi-asserted-by":"crossref","first-page":"e673","DOI":"10.1161\/CIR.0000000000000709","article-title":"Omega-3 fatty acids for the Management of Hypertriglyceridemia: A science advisory from the American Heart Association","volume":"140","author":"Skulas-Ray","year":"2019","journal-title":"Circulation"},{"issue":"19","key":"10.1016\/j.pharmthera.2023.108544_bb0480","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1161\/01.CIR.98.19.2088","article-title":"Mechanism of action of fibrates on lipid and lipoprotein metabolism","volume":"98","author":"Staels","year":"1998","journal-title":"Circulation"},{"issue":"4a","key":"10.1016\/j.pharmthera.2023.108544_bb0485","doi-asserted-by":"crossref","first-page":"66b","DOI":"10.1016\/S0002-9149(98)00041-1","article-title":"Comparison of statins in hypertriglyceridemia","volume":"81","author":"Stein","year":"1998","journal-title":"The American Journal of Cardiology"},{"issue":"1","key":"10.1016\/j.pharmthera.2023.108544_bb0490","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1194\/jlr.M400296-JLR200","article-title":"Relation of the size and intracellular sorting of apoB to the formation of VLDL 1 and VLDL 2","volume":"46","author":"Stillemark-Billton","year":"2005","journal-title":"Journal of Lipid Research"},{"issue":"12","key":"10.1016\/j.pharmthera.2023.108544_bb0495","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1056\/NEJMoa1507652","article-title":"Coding variation in ANGPTL4, LPL, and SVEP1 and the risk of coronary disease","volume":"374","author":"Stitziel","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2023.108544_bb0500","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1111\/dom.14328","article-title":"Effects of liraglutide on the metabolism of triglyceride-rich lipoproteins in type 2 diabetes","volume":"23","author":"Taskinen","year":"2021","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"16","key":"10.1016\/j.pharmthera.2023.108544_bb0505","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJMoa1804989","article-title":"Effects of n\u22123 fatty acid supplements in diabetes mellitus","volume":"379","author":"The","year":"2018","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2023.108544_bb0515","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/862504","article-title":"The effect of alcohol on postprandial and fasting triglycerides","volume":"2012","author":"Van de Wiel","year":"2012","journal-title":"International Journal of Vascular Medicine"},{"issue":"47","key":"10.1016\/j.pharmthera.2023.108544_bb0520","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1093\/eurheartj\/ehab293","article-title":"Directly measured vs. calculated remnant cholesterol identifies additional overlooked individuals in the general population at higher risk of myocardial infarction","volume":"42","author":"Varbo","year":"2021","journal-title":"European Heart Journal"},{"issue":"9","key":"10.1016\/j.pharmthera.2023.108544_bb0525","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jacc.2021.06.011","article-title":"2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: A report of the American College of Cardiology Solution set Oversight Committee","volume":"78","author":"Virani","year":"2021","journal-title":"Journal of the American College of Cardiology"},{"issue":"Pt 2","key":"10.1016\/j.pharmthera.2023.108544_bb0530","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1042\/bj2840457","article-title":"The lipolysis\/esterification cycle of hepatic triacylglycerol. Its role in the secretion of very-low-density lipoprotein and its response to hormones and sulphonylureas","volume":"284","author":"Wiggins","year":"1992","journal-title":"The Biochemical Journal"},{"issue":"11","key":"10.1016\/j.pharmthera.2023.108544_bb0535","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly Semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1016\/j.pharmthera.2023.108544_bb0540","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1016\/j.pharmthera.2023.108544_bb0545","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1161\/CIRCRESAHA.120.317128","article-title":"LDL-cholesterol reduction by ANGPTL3 inhibition in mice is dependent on endothelial lipase","volume":"127","author":"Wu","year":"2020","journal-title":"Circulation Research"},{"issue":"3","key":"10.1016\/j.pharmthera.2023.108544_bb0550","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1161\/ATVBAHA.117.310473","article-title":"APOC3 loss-of-function mutations, remnant cholesterol, low-density lipoprotein cholesterol, and cardiovascular risk: mediation- and meta-analyses of 137895 individuals","volume":"38","author":"Wulff","year":"2018","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"issue":"9567","key":"10.1016\/j.pharmthera.2023.108544_bb0555","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomised open-label, blinded endpoint analysis","volume":"369","author":"Yokoyama","year":"2007","journal-title":"The Lancet"},{"issue":"6","key":"10.1016\/j.pharmthera.2023.108544_bb0560","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/0026-0495(95)90193-0","article-title":"Change in skeletal muscle lipoprotein lipase activity in response to insulin\/glucose in non-insulin-dependent diabetes mellitus","volume":"44","author":"Yost","year":"1995","journal-title":"Metabolism"},{"issue":"2","key":"10.1016\/j.pharmthera.2023.108544_bb0565","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2217\/17460875.1.2.227","article-title":"Fasting-induced adipose factor\/angiopoietin\u2013like protein 4: A potential target for dyslipidemia?","volume":"1","author":"Zandbergen","year":"2006","journal-title":"Future Lipidology"},{"issue":"10","key":"10.1016\/j.pharmthera.2023.108544_bb0570","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1210\/me.2015-1155","article-title":"Minireview: Roles of fibroblast growth factors 19 and 21 in metabolic regulation and chronic diseases","volume":"29","author":"Zhang","year":"2015","journal-title":"Molecular Endocrinology"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725823002085?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725823002085?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:40:44Z","timestamp":1759012844000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725823002085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":114,"alternative-id":["S0163725823002085"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108544","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Severe hypertriglyceridemia: Existing and emerging therapies","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108544","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108544"}}